$0.93
-0.03 (-3.11%)
Open$0.97
Previous Close$0.96
Day High$0.97
Day Low$0.93
52W High$2.38
52W Low$0.27
Volume—
Avg Volume744.8K
Market Cap46.65M
P/E Ratio—
EPS$-0.73
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+4,235.5% upside
Current
$0.93
$0.93
Target
$40.32
$40.32
$26.90
$40.32 avg
$53.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.73M | 5.14M | 4.74M |
| Net Income | -102,176,432 | 951.6K | 665.5K |
| Profit Margin | -3,740.9% | 18.5% | 14.0% |
| EBITDA | -102,471,540 | 1.31M | 1.24M |
| Free Cash Flow | — | 380.5K | 530.0K |
| Rev Growth | — | -9.9% | +8.5% |
| Debt/Equity | 0.36 | 0.11 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |